GIP-Overexpressing Mice Demonstrate Reduced Diet-Induced Obesity and Steatosis, and Improved Glucose Homeostasis
Open accessThe DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Abstract
Glucose-dependent insulinotropic polypeptide (GIP) is a gastrointestinal hormone that potentiates glucose-stimulated insulin secretion during a meal. Since GIP has also been shown to exert β-cell prosurvival and adipocyte lipogenic effects in rodents, both GIP receptor agonists and antagonists have been considered as potential therapeutics in type 2 diabetes (T2DM). In the present study, we tested the hypothesis that chronically elevating GIP levels in a transgenic (Tg) mouse model would increase adipose tissue expansion and exert beneficial effects on glucose homeostasis. In contrast, although GIP Tg mice demonstrated enhanced β-cell function, resulting in improved glucose tolerance and insulin sensitivity, they exhibited reduced diet-induced obesity. Adipose tissue macrophage infiltration and hepatic steatosis were both greatly reduced, and a number of genes involved in lipid metabolism/inflammatory signaling pathways were found to be down-regulated. Reduced adiposity in GIP Tg mice was associated with decreased energy intake, involving overexpression of hypothalamic GIP. Together, these studies suggest that, in the context of over-nutrition, transgenic GIP overexpression has the potential to improve hepatic and adipocyte function as well as glucose homeostasis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“The precise effects of GIP on lipid metabolism are currently unclear; some studies suggest it may increase lipid uptake in adipose tissue and decrease lipolysis [53,54], while others suggest GIP may have lipolytic activity, as adipose tissue from transgenic mice overexpressing GIP has been found to be resistant to high-fat feeding [55,56].”
From New Developments in Pharmacological Treatment of Obesity and Type 2 Diabetes—Beyond and within GLP-1 Receptor Agonists (2024) · cites this paper as [56]
In the citing paper
“Notwithstanding, significant general GIP overexpression prevents obesity and lowers inflammatory markers in mice [123].”
From Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance (2024) · cites this paper as [123]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371 · cited 1×
“gastric emptying and food intake [5–9].”
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Kahn, S. E., Haffner, S. M., Heise, M. A., Herman, W. H., Holman, R. R., Jones, N. P., Kravitz, B. G., Lachin, J. M., O'Neill, M. C., Zinman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa066224 · Cited by 2,962 · cited 1×
“needed [3–4].”
Type 2 diabetes: principles of pathogenesis and therapy
Stumvoll, M., Goldstein, B. J., & van Haeften, T. W. (2005) · The Lancet · doi:10.1016/s0140-6736(05)61032-x · Cited by 2,662 · cited 1×
“lowering carbohydrate digestion [1–2].”
Obesity-associated improvements in metabolic profile through expansion of adipose tissue
Kim, J.-Y., van de Wall, E., Laplante, M., Azzara, A., Trujillo, M. E., Hofmann, S. M., Schraw, T., Durand, J. L., Li, H., Li, G., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31021 · Cited by 1,310 · cited 1×
“In a recent study, it was demonstrated that overexpression of adiponectin in mice on an ob/ob genetic background resulted in greater obesity, compared to non-transgenic animals, but with marked improvements in both glucose tolerance and insulin resistance, as well as reduced circulating TG and hepatic steatosis [31].”
BackgroundMitochondrial biogenesis in mammals: the role of endogenous nitric oxide
Nisoli, E., Clementi, E., Paolucci, C., Cozzi, V., Tonello, C., Sciorati, C., Bracale, R., Valerio, A., Francolini, M., Moncada, S., et al. (2003) · Science · doi:10.1126/science.1079368 · Cited by 1,243 · cited 1×
“eNos has been linked to the induction of PGC-1a expression [38–39] and both PGC-1a [40] and Ucp2 [41] are involved in mitochondrial biogenesis, reduction of which may contribute to lowering ROS production.”
BackgroundInhibition of gastric inhibitory polypeptide signaling prevents obesity
Miyawaki, K., Yamada, Y., Ban, N., Ihara, Y., Tsukiyama, K., Zhou, H., Fujimoto, S., Oku, A., Tsuda, K., Toyokuni, S., et al. (2002) · Nature Medicine · doi:10.1038/nm727 · Cited by 963 · cited 3×
“No significant differences in energy expenditure, determined by indirect calorimetry, were apparent between Het GIP Tg mice and WT littermates on either LF or HF diets (Figure 5A and Figure S1), whereas higher energy expenditure was reported for GIPRKO mice [22].”
BackgroundMethodResultThe role of gut hormones in glucose homeostasis
Drucker, D. J. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30076 · Cited by 614 · cited 1×
“gastric emptying and food intake [5–9].”
Sethi, J. K., & Vidal-Puig, A. J. (2007) · Journal of Lipid Research · doi:10.1194/jlr.r700005-jlr200 · Cited by 563
Brubaker, P. L., & Drucker, D. J. (2004) · Endocrinology · doi:10.1210/en.2004-0015 · Cited by 540
Miyawaki, K., Yamada, Y., Yano, H., Niwa, H., Ban, N., Ihara, Y., Kubota, A., Fujimoto, S., Kajikawa, M., Kuroe, A., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.26.14843 · Cited by 454 · cited 1×
“In view of the glucose intolerance but resistance to diet-induced obesity observed in GIPR knockout mice [22,33–34], the current study was initiated to test the hypothesis that chronically elevating GIP levels in vivo would increase adipose tissue expansion and exert beneficial effects on glucose homeostasis.”
Background
Cited by
Items 101–183 of 183
The role of incretins and incretin-based drugs in autoimmune diseases
Radbakhsh, S., Atkin, S. L., Simental‐Mendía, L. E., & Sahebkar, A. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107845 · Cited by 24
Holst, J. J. (2021) · Diabetes · doi:10.2337/dbi21-0026 · Cited by 23
“However, in rodent studies overexpression of GIP and administration of long-acting GIP agonists have been reported to enhance insulin sensitivity (42,43).”
BackgroundSelectivity of peptide ligands for the human incretin receptors expressed in HEK-293 cells
Al‐Sabah, S., Al-Fulaij, M. A., & Ahmed, H. A. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.08.019 · Cited by 23
Pro-inflammatory gene expression profile in obese adults with high plasma GIP levels
Góralska, J., Raźny, U., Polus, A., Stancel-Możwiłło, J., Chojnacka, M., Gruca, A., Zdzienicka, A., Dembińska-Kieć, A., Kieć-Wilk, B., Solnica, B., et al. (2018) · International Journal of Obesity · doi:10.1038/ijo.2017.305 · Cited by 22
Murata, Y., Harada, N., Kishino, S., Iwasaki, K., Ikeguchi, E., Yamane, S., Kato, T., Kanemaru, Y., Sankoda, A., Hatoko, T., et al. (2021) · iScience · doi:10.1016/j.isci.2021.102963 · Cited by 26
“In contrast, studies using GIP-overexpressing mice or GIP agonist have shown that pharmacological activation of GIP signaling is beneficial for suppression of body weight gain and insulin resistance (Kim et al., 2012; Mroz et al., 2019).”
BackgroundRoles of glucose‐dependent insulinotropic polypeptide in diet‐induced obesity
Seino, Y., & Yamazaki, Y. (2022) · Journal of Diabetes Investigation · doi:10.1111/jdi.13816 · Cited by 22
Cardiovascular biology of the GIP receptor
Greenwell, A. A., Chahade, J. J., & Ussher, J. R. (2019) · Peptides · doi:10.1016/j.peptides.2019.170228 · Cited by 24
Twincretin as a potential therapeutic for the management of type 2 diabetes with obesity
Usui, R., Yabe, D., & Seino, Y. (2019) · Journal of Diabetes Investigation · doi:10.1111/jdi.13005 · Cited by 20
Efimova, I., Steinberg, I., Zvibel, I., Neumann, A., Mantelmacher, F. D., Drucker, D. J., Fishman, S., & Varol, C. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.643144 · Cited by 22
Perspectives on weight control in diabetes – Tirzepatide
Várkonyi, T. T., Pósa, A., Pávó, N., & Pavo, I. J. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110770 · Cited by 22
“In a transgenic mouse model, on the other hand, the chronically elevated GIP concentration resulted in increased insulin sensitivity, better glucose tolerance, enhanced β-cell function and weight loss [48].”
BackgroundThe role of GIPR in food intake control
James-Okoro, P.-P., Lewis, J. E., Gribble, F. M., & Reimann, F. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1532076 · Cited by 23
Regulation of energy metabolism through central GIPR signaling
Liśkiewicz, A., & Müller, T. D. (2024) · Peptides · doi:10.1016/j.peptides.2024.171198 · Cited by 18
“Mice with overexpression of GIP show decreased body weight when fed with a high-fat diet (HFD) [50], and although GIP promotes lipogenesis in cultured adipocytes under conditions of hyperinsulinemia [39 – 41], it stimulates lipolysis under conditions or normo-or hypoinsulinemia in cultured…”
Suzuki, T., Sato, T., Tanaka, M., Endo, K., Nakata, K., Ogawa, T., Hosaka, I., Akiyama, Y., Umetsu, A., & Furuhashi, M. (2024) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2024.108779 · Cited by 18
Chronic GIPR agonism results in pancreatic islet GIPR functional desensitisation
Davies, I., Adriaenssens, A. E., Scott, W. R., Carling, D., Murphy, K. G., MINNION, J. S., Bloom, S. R., Jones, B. J., & Tan, T. (2025) · Molecular Metabolism · doi:10.1016/j.molmet.2025.102094 · Cited by 20
Khajavi, N., Biebermann, H., Tschöp, M., & DiMarchi, R. (2017) · Endocrine Development · doi:10.1159/000475737 · Cited by 16
Reprint of: Recent Updates on Obesity Treatments: Available Drugs and Future Directions
Dragano, N. R. V., Fernø, J., Diéguez, C., López, M., & Milbank, E. (2020) · Neuroscience · doi:10.1016/j.neuroscience.2020.08.009 · Cited by 21
De Fano, M., Malara, M., Vermigli, C., & Murdolo, G. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25168650 · Cited by 17
“Notwithstanding, significant general GIP overexpression prevents obesity and lowers inflammatory markers in mice [123].”
BackgroundSnook, L. A., Nelson, E. M., Dyck, D. J., Wright, D. C., & Holloway, G. P. (2015) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00003.2015 · Cited by 17
“Inhibition of GIP signaling, or ablation of the GIP receptor (GIPR), impairs glucose homeostasis (16, 27, 44), and conversely, GIP overexpression improves glucose homeostasis in the face of a high-fat diet challenge (20), highlighting the importance of GIP in regulating postprandial fuel homeostasis.”
BackgroundKubota, M., Yamamoto, K., & Yoshiyama, S. (2023) · Cureus · doi:10.7759/cureus.46490 · Cited by 16
“Regarding effects on body weight, it was reported that at physiological concentrations GIP promotes fat accumulation in a mouse model [16], but at pharmacological concentrations, it suppresses appetite and reduces body weight [17].”
BackgroundGut hormone multi-agonists for the treatment of type 2 diabetes and obesity: advances and challenges
Huang, X., Liu, J., Peng, G., Lu, M., Zhou, Z., Jiang, N., & Yan, Z. (2024) · Journal of Endocrinology · doi:10.1530/joe-23-0404 · Cited by 20
GIP(3-30)NH2 – a tool for the study of GIP physiology
Lynggaard, M. B., Gasbjerg, L. S., Christensen, M., & Knop, F. K. (2020) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2020.08.011 · Cited by 17
Therapeutic Potential of G Protein‐Coupled Receptors Against Nonalcoholic Steatohepatitis
Sun, D., Yang, X., Wu, B., Zhang, X., Li, H., & She, Z. (2021) · Hepatology · doi:10.1002/hep.31852 · Cited by 17
Physiology and clinical applications of GIP
Yamane, S., Harada, N., & Inagaki, N. (2025) · Endocrine Journal · doi:10.1507/endocrj.ej25-0087 · Cited by 16
“…GIP, it has been shown that trans‐ genic mice overexpressing GIP exhibit a significant decrease in weight gain after ingestion of an HFD, sug‐ gesting that chronic elevation of GIP levels well above physiological concentrations may exert a centrally medi‐ ated suppressive effect on appetite [124].”
Quiñones, M., Fernø, J., Diéguez, C., Nogueiras, R., & Al–Massadi, O. (2019) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2019.1583642 · Cited by 14
“experiments with transgenic overexpression of GIP in mice [93], GIP agonists and co-agonists or GIP in combination with”
BackgroundPharmacological Advances in Incretin-Based Polyagonism: What We Know and What We Don’t
Novikoff, A., & Müller, T. D. (2024) · Physiology · doi:10.1152/physiol.00032.2023 · Cited by 15
Tirzepatide for Weight Loss: Can Medical Therapy “Outweigh” Bariatric Surgery?
Novograd, J., Mullally, J. A., & Frishman, W. H. (2023) · Cardiology in Review · doi:10.1097/crd.0000000000000515 · Cited by 12
RISING STARS: Targeting G protein-coupled receptors to regulate energy homeostasis
Jamaluddin, A., & Gorvin, C. M. (2023) · Journal of Molecular Endocrinology · doi:10.1530/jme-23-0014 · Cited by 12
The Enteroendocrine System in Obesity
Miedzybrodzka, E. L., Reimann, F., & Gribble, F. M. (2022) · Handbook of experimental pharmacology · doi:10.1007/164_2022_582 · Cited by 12
A Mechanistic Rationale for Incretin-Based Therapeutics in the Management of Obesity
Samms, R. J., & Kusminski, C. M. (2024) · Annual Review of Physiology · doi:10.1146/annurev-physiol-022724-105443 · Cited by 12
Haspula, D., & Cui, Z. (2023) · Cells · doi:10.3390/cells12131801 · Cited by 14
Rodriguez, N. S., & Hartmann, P. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100058 · Cited by 13
Rieger, T. R., & Musante, C. J. (2016) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2016.05.006 · Cited by 10
Gut Peptide Agonism in the Treatment of Obesity and Diabetes
Grandl, G., Novikoff, A., DiMarchi, R. D., Tschöp, M. H., & Müller, T. D. (2019) · Comprehensive physiology · doi:10.1002/cphy.c180044 · Cited by 11
Davies, I., & Tan, T. (2023) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2023.2203911 · Cited by 10
“Kim et al showed that transgenic mice overexpressing GIP, contrary to expectation, were significantly lighter than WT mice when fed a HFD [39].”
BackgroundKim, M.-K., & Kim, H. S. (2024) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2024.228 · Cited by 10
The unexpected role of GIP in transforming obesity treatment
Zandvakili, I., & Pérez–Tilve, D. (2024) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2024.07.022 · Cited by 9
Hatoko, T., Harada, N., Tokumoto, S., Yamane, S., Ikeguchi, E., Kato, T., Yasuda, T., Tatsuoka, H., Shimazu‐Kuwahara, S., Yabe, D., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-22511-7 · Cited by 8
Current State of Pharmacotherapy in Obesity
Kim, W. J. (2024) · Korean Journal of Gastroenterology · doi:10.4166/kjg.2024.016 · Cited by 10
He, X. (2022) · European Journal of Inflammation · doi:10.1177/20587392211070402 · Cited by 7
“In addition, interpretation of anti-inflammatory findings in two of the in vivo rodent experiments is complicated as most studies also reported weight loss or lesser weight gain as a result of the GIP treatment: GIP-induced weight loss may have resulted in reduced inflammation rather than any direct effects of GIP sig…”
BackgroundResultInfluentialGaffey, R. H., Takyi, A. K., & Shukla, A. P. (2024) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2024.2377319 · Cited by 8
“First is the potential to safely expand adipose tissue in a way that does not predispose to inflammation and insulin resistance Therefore, this function may be preserved even if an agonist is a functional antagonist at other tissues as described above [87,88].”
Regulation of feeding and therapeutic application of bioactive peptides
Ueno, H., Zhang, W., & Nakazato, M. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108187 · Cited by 7
“Overexpression of GIP in HFD-induced obese mice resulted in weight loss and decreased blood glucose levels (Kim et al., 2012).”
Duodenal enteroendocrine cells and GIP as treatment targets for obesity and type 2 diabetes
Bailey, C. J., & Flatt, P. R. (2024) · Peptides · doi:10.1016/j.peptides.2024.171168 · Cited by 6
Jiménez-Martí, E., Hurtado-Genovés, G., Aguilar-Ballester, M., Martínez‐Hervás, S., & Navarro, H. G. (2022) · Nutrients · doi:10.3390/nu14183775 · Cited by 7
“These beneficial effects consisted of a concomitant improved glucose homeostasis and insulin sensitivity as well as the down-regulation gene expression of lipid metabolism and inflammatory signalling pathways [83].”
BackgroundAvgerinos, I., Kakotrichi, P., Karagiannis, T., Bekiari, E., & Τσάπας, Α. (2024) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2024.2324918 · Cited by 7
“In particular, studies in db/db mice and rodents yielded increased glucose-lowering and insulinotropic efficacy of a dual GIP and GLP-1 receptor agonist peptide compared to selective GLP-1 agonists [27].”
BackgroundIncretin Hormones in the Control of Immunometabolism
Fishman, S., Zvibel, I., & Varol, C. (2019) · Immunometabolism · doi:10.20900/immunometab20190004 · Cited by 6
“In contrast, HFD-fed mice with enhanced genetic expression of GIP exhibited reduced ATM infiltration and pro-inflammatory cytokine expression and an ameliorated metabolic phenotype [160].”
BackgroundThe GIPR is Predominantly Localized to Non-Adipocyte Cell Types Within White Adipose Tissue
Campbell, J. E., Beaudry, J. L., Svendsen, B., Baggio, L. L., Gordon, A. N., Ussher, J. R., Wong, C. K., Gribble, F. M., D’Alessio, D. A., Reimann, F., et al. (2022) · doi:10.2337/figshare.19184462 · Cited by 6
Morais, T., Seabra, A. L., Patrício, B. G., Carrageta, D. F., Guimarães, M., Nora, M. C., Oliveira, P. F., Alves, M. G., & Monteiro, M. P. (2023) · Metabolites · doi:10.3390/metabo13050587 · Cited by 5
“Within the AT, GIP also stimulates glucose uptake [13], insulin sensitivity [14] and blood flow [15,16].”
BackgroundSue, M., Watanabe, M., Inoue, A., Katayama, A., Teshigawara, S., Matsushita, Y., Takeda, M., Iseda, I., Eguchi, J., & Hida, K. (2025) · Clinical Case Reports · doi:10.1002/ccr3.70173 · Cited by 4
Revitalizing GIP: Therapeutic Potential in Metabolic and Neurodegenerative Disorders
Qiao, Y., Zhou, F., Mao, T., & Gao, L. (2026) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s559587 · Cited by 4
Pancreatic β Cells in Metabolic Syndrome
Hiriart, M., Velasco, M., Díaz‐García, C. M., Larqué, C., Sánchez-Soto, C., Albarado-Ibáñez, A., Chávez‐Maldonado, J. P., Toledo, A., & García-Delgado, N. (2014) · Springer eBooks · doi:10.1007/978-94-007-6686-0_27 · Cited by 4
Bauri, R., Bele, S. D., Edelli, J., Reddy, N. C., Kurukuti, S., Devasia, T., Ibrahim, A., Rai, V., & Mitra, P. (2024) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00474.2023 · Cited by 4
A metabolic comparison of GIPR agonism versus GIPR antagonism in male mice
Davies, I., Turland, A., Tran, H. D., Wong, C., Cahn, O., Dunsterville, C., Sun, Y., Xiao, Y., Murphy, K. G., Bloom, S. R., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70300 · Cited by 3
Nutritional Impact on Anabolic and Catabolic Signaling
Székely, M., Soós, S., Pétervári, E., & Balaskó, M. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-801816-3.00014-5 · Cited by 7
Hormones and Gastrointestinal Function of Newborns
Prodam, F., Bellone, S., Ricotti, R., Monzani, A., Genoni, G., Giglione, E., & Bona, G. (2016) · Springer eBooks · doi:10.1007/978-3-319-18159-2_184-1 · Cited by 3
Pancreatic islet remodeling in cotadutide-treated obese mice
Spezani, R., Marinho, T. D. S., Cardoso, L. E. M., Águila, M. B., & Mandarim‐de‐Lacerda, C. A. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.121858 · Cited by 3
Tirzepatide protects against hepatic oxidative stress in high-fat induced obesity in male rats
Alathary, A. J., & Al-Isawi, Z. J. K. (2024) · Maaen Journal for Medical Sciences · doi:10.55810/2789-9136.1053 · Cited by 4
Scaling it down: new in vitro tools to get the balance right
Biggs, E. K., Gribble, F. M., & Reimann, F. (2016) · Biochemical Journal · doi:10.1042/bcj20160874 · Cited by 3
Sauter, E. R., & Agurs‐Collins, T. (2024) · Cancers · doi:10.3390/cancers16193275 · Cited by 2
“Mice that overexpress GIP demonstrate increased β -cell function, decreased insulin resistance, as well as reduced obesity [35].”
BackgroundBesci, Ö., Güler, M. Ç., Foss‐Freitas, M. C., & Oral, E. A. (2025) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2025.2574318 · Cited by 3
“Despite conflicting findings from murine studies regarding their role in obesity [126,127], this dual mechanism of tirzepatide has demonstrated significant therapeutic benefits in patients with lipodystrophy syndromes [128].”
The Paradox and Future of GLP-1/GIP Combination Therapies: Efficacy and Mechanisms
Davies, I., Holst, J. J., ROSENKILDE, M. M., & Tan, T. (2026) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-061824-043740 · Cited by 3
Reijne, A. C., Talarovičová, A., Coolen, A., Bruggink, J. E., Čiapaitė, J., Bleeker, A., Groen, A. K., Reijngoud, D., Bakker, B. M., & van Dijk, G. (2022) · Nutrition and Healthy Aging · doi:10.3233/nha-220163 · Cited by 2
GIP und GLP-1-Rezeptoragonismus in der Therapie des Typ 2 Diabetes mit Fokus auf Tirzepatid
Nauck, M. A., Blüher, M., Meyhöfer, S. M., Heitmann, E., & Görgens, S. W. (2023) · Diabetologie und Stoffwechsel · doi:10.1055/a-2102-2436 · Cited by 3
“Es gibt einander widersprechende Tierstudien, die zeigen, dass sowohl GIPR-Knockout-Tiere (fehlender GIPR-Agonismus) als auch transgene Mäuse mit einer chronischen Überexpression von GIP (verstärkter GIPR-Agonismus) resistent gegen eine Nahrungs-induzierte Fett-leibigkeit sind [14, 70].”
BackgroundMi, L., Li, T., Xiang, X., Zhou, Y., Xiong, N., Chen, Y., Chen, J., Shang, S., Chen, S., Cheung, W. W., et al. (2025) · Journal of Advanced Research · doi:10.1016/j.jare.2025.09.009 · Cited by 2
“Both GLP-1R and GIPR signaling pathways are important for metabolic regulation [9,15–17].”
Kohda, Y., Minamigawa, C., Matsuo, M., & Matsumura, H. (2016) · Fundamental Toxicological Sciences · doi:10.2131/fts.3.291 · Cited by 2
“It has been previously reported that transgenic GIP over expression has the potential to improved glucose homeostasis (Kim et al., 2012).”
BackgroundKohda, Y. (2020) · Fundamental Toxicological Sciences · doi:10.2131/fts.7.291 · Cited by 2
“As previously reported, GIP activates lipoprotein lipase (Kim et al., 2007, 2012), suggesting that GIP expressed in the liver may be involved in glycolipid metabolism.”
Tirzepatide‐induced body composition changes: Implications from the SURPASS ‐3 MRI substudy
Yen, I., & Li, H. (2026) · Journal of Diabetes Investigation · doi:10.1111/jdi.70232 · Cited by 1
Beyond glycemic control: clinical cardiovascular effects of tirzepatide—a narrative review
Alawad, A. O., Merghani, T. H., Fadelelmoula, T. E. Y., Elamin, N. A., Satti, S., Edris, A., Hakim, A., El-Hindi, R. F., Alhaj-Ali, A. A., Ibrahim, W. E., et al. (2026) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188261469947 · Cited by 1
Pancreatic Beta Cells in Metabolic Syndrome
Hiriart, M., Velasco, M., Díaz‐García, C. M., Larqué, C., Sánchez-Soto, C., Albarado-Ibáñez, A., Chávez‐Maldonado, J. P., Toledo, A., & García-Delgado, N. (2014) · Springer eBooks · doi:10.1007/978-94-007-6884-0_27-2 · Cited by 1
Polypharmakologie als ein neuer Ansatz zur Präzisionsmedizin in der Adipositas- und Diabetestherapie
Jall, S., Götz, A., Tschöp, M., & Müller, T. D. (2018) · Adipositas - Ursachen Folgeerkrankungen Therapie · doi:10.1055/s-0038-1654054 · Cited by 2
The integrity of the FOG‐2 LXCXE pRb‐binding motif is required for small intestine homeostasis
Goupille, O., Kadri, Z., Langelé, A., Luccantoni, S., Badoual, C., Leboulch, P., & Chrétien, S. (2019) · Experimental Physiology · doi:10.1113/ep087369 · Cited by 1
“GIP is a proximal intestinal enteroendocrine peptide, the precise role of which in resistance to diet-induced obesity and steatosis remains a matter of debate (Althage et al., 2008; Kim et al., 2012).”
BackgroundDifferences in GIP Receptor Expression by Feeding Status in the Mouse Brain
Song, D. K., Jung, N., Sung, Y., Hong, Y. S., & Lee, H. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26031142 · Cited by 1
Pancreatic b Cells in Metabolic Syndrome 30
Hiriart, M., Velasco, M., Díaz‐García, C. M., Larqué, C., & Toledo, A. (2015)
Generation and use of new tools for the characterisation of gut hormone receptors
Biggs, E. K. (2018) · Apollo (University of Cambridge) · doi:10.17863/cam.37487
Utilising the therapeutic potential of xenin and related molecules for diabetes and obesity
Craig, S. L. (2020) · Ulster University Research Portal (Ulster University)
Hormones and Gastrointestinal Function of Newborns
Prodam, F., Bellone, S., Ricotti, R., Monzani, A., Genoni, G., Giglione, E., & Bona, G. (2018) · Springer eBooks · doi:10.1007/978-3-319-29489-6_184
Mechanism of Incretin Secretion via Fatty Acid Receptors
Yamane, S., & Harada, N. (2023) · Nippon Eiyo Shokuryo Gakkaishi · doi:10.4327/jsnfs.76.133
Physiological Effects of Incretin and Its Regulation and Imitation by Functional Food Factors
Harada, N. (2023) · Nippon Eiyo Shokuryo Gakkaishi · doi:10.4327/jsnfs.76.141
Xia, X., Lin, Q., Zhou, Z. M., & Chen, Y. (2024) · iScience · doi:10.1016/j.isci.2024.109377 · Cited by 2
Contrasting roles for GLP-1R and GIPR in a model of diet-induced obesity
Gao, J., Cree, S., Ham, S., Nowell, C. J., Parker, A., Zhao, P., Whiting, L., Sloop, K. W., Samms, R. J., Sexton, P. M., et al. (2025) · Journal of Molecular Endocrinology · doi:10.1530/jme-25-0053
Zhou, Q., Lei, X., Fu, S., Liu, P., Long, C., Wang, Y., Li, Z., Xie, Q., & Chen, Q. (2024) · Figshare · doi:10.6084/m9.figshare.26633796
Adaptive changes of human islets to an obesogenic environment in the mouse
Gargani, S. (2013) · theses.fr (ABES) · doi:10.70675/cebf7176z1bb8z414bzb159ze850f327d2d5
“Furthermore, overexpression of GIP in transgenic mice increases beta cell function and improves insulin sensitivity, but mice were resistant to HF diet-induced glucose intolerance [98].”
Fakhir, S. D., Arif, I. S., Alqallaf, S. M., & Waheed, H. J. (2026) · Al Mustansiriyah Journal of Pharmaceutical Sciences · doi:10.32947/ajps.v26i1.1347
Metadata
- Authors
- Kim, S.-J., Nian, C., Karunakaran, S., Clee, S. M., Isales, C. M., & McIntosh, C. H. S.
- Affiliations
- University of British Columbia (CA)
- Corresponding author
- McIntosh, Christopher H. S.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2012-07-03
- Volume
- 7
- Issue
- 7
- Pages
- e40156
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3388996
- OpenAlex
- W2072686461
- Cited by
- 182
- References
- 55
- Citations by year
- 2026: 5 · 2025: 11 · 2024: 28 · 2023: 18 · 2022: 18 · 2021: 14 · 2020: 17 · 2019: 21 · 2018: 12 · 2017: 5 · 2016: 13 · 2015: 5 · 2014: 7 · 2013: 7 · 2012: 1
- FWCI
- 4.77
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- Canadian Diabetes Association
- Michael Smith Health Research BC
- Canadian Institutes of Health Research
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Physiology (medical) › Adipose Tissue and Metabolism
- Keywords
- glucose-dependent insulinotropic polypeptide, diet-induced obesity, hepatic steatosis, glucose homeostasis, insulin sensitivity, beta-cell function, adipose tissue macrophage infiltration, energy intake, lipid metabolism, inflammation, type 2 diabetes, transgenic mice
- MeSH terms
- Adipose Tissue, Animals, Energy Metabolism, Fatty Liver, Gastric Inhibitory Polypeptide, Glucose, Glucose Tolerance Test, Homeostasis, Insulin Resistance, Male, Mice, Transgenic, Obesity, Glucose Intolerance, Mice, Diet, High-Fat
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.